Stock Exchange Listing
Tel: 1 (877) 299-4603
Tel: (519) 858-5184
Fax: (519) 858-5099
Tel: (604) 961-2939
Ray Matthews & Associates, Inc.
Tel: (604) 818-7778
700 Collip Circle, Ste 114
Canada N6G 4X8
Sernova was founded in 2006
Sernova’s Cell Pouch™, combined with its local immune protection technology, offers therapeutic cells local protection from immune system attack creating an effective, safe, long-term and convenient therapeutic option for patients with chronic disease who seek to improve their quality of life.
Latest Press Releases
Sernova Completes Oversubscribed Private Placement of $2,754,000 / July 23, 2018
Sernova Announces $2,000,000 First Closing of Private Placement / July 16, 2018
Sernova Announces $2 Million Private Placement Financing / June 26, 2018
All Press Releases →
Sernova is committed to the development and clinical advancement of its products for chronic diseases using therapeutic cells transplanted into an implanted medical device, forming a natural environment promoting long term function of the therapeutic cells. The company’s management believes in building strong and long-lasting collaborations and partnerships that would lead to the rapid advancement of Sernova’s portfolio of products into the market, improving global health and bringing value to patients and society.
All Updates →
Cell Pouch System™
Sernova’s Cell Pouch System™ is a novel implantable and scalable medical device which forms a natural environment in the body for the housing and long-term survival and function of therapeutic cells. These therapeutic cells release necessary proteins or hormones missing from the body to treat chronic diseases as an alternative to daily administration of drugs.Read More...
Sernova has multiple options for protection of cells within the Cell Pouch from immune system attack. The cells can be protected using medications that protect the cells from immune attack. There are polymer encapsulation technologies to protect the cells from the immune system. There are also developing methodologies to make cells unrecognizable to the immune system. These latter two technologies may not require medications to protect the cells from the immune system.Read More ...
Dr. Philip M. Toleikis
President and CEO
BA, MSc, PhD
Dr. Toleikis is currently President and Chief Executive Officer of Sernova Corp since April 2009. From 2006 until 2009, Dr. Toleikis consulted for multiple device, combination product and pharmaceutical companies. From 1996 to 2006 he held multiple roles at Angiotech Pharmaceuticals, Inc. including Vice President, Research and Development - Pharmacology and Drug Screening where he built a product development team of over 50 scientists and was responsible for multiple corporate and academic product development collaborations.
While at Sernova, Dr. Toleikis has secured over $20 million in various forms of financings, including equity raises and multiple non-dilutive grants and has been responsible for negotiating a worldwide exclusive license with UHN for its stem cell derived technologies as well as developing business relationships and or collaborations with multiple pharmaceutical and academic institutions involving its Cell Pouch™ device and cell technologies.
Dr. Toleikis is the author of multiple issued patents, over 110 patent applications, and multiple scientific publications involving transplantation, metabolic, cardiovascular, oncology, and autoimmune disease. He obtained his Ph.D. in Medicine, Pharmacology and Therapeutics from the University of British Columbia, his M.Sc. at the University of Michigan and B.A. at the University of Vermont.
Among a number of volunteer activities he is a speaker at JDRF events, and a community member of UHP school council in London, Ontario.Go back
Sernova was founded in 2006 - London, Ontario;
On September 20, the Company announced it had received TSX Venture Exchange approval to change its name to Sernova Corp.
In April the Board of Directors brought in a new management team to find viable research and development projects suitable for the Company. On May 16, 2006 the Company announced it had closed a joint venture agreement with Sertonex Inc., a private medical research company based in London Ontario, and Sertoli Technology Inc., a private intellectual property company based in Tucson Arizona. The joint venture allows the Company to own the exclusive rights to the research efforts and intellectual property related to a potential breakthrough treatment for diabetes. That project is now the Company's main focus.
On May 4th, Pheromone Sciences Corp announced the conclusion of negotiations with HealthWatchSystems, Inc. of Sarasota, Florida for the sale of all patents, intellectual property and supplies related to the Fertility Monitor. At the company's annual and special shareholder meeting on August 25, 2004, the sale was accepted by the shareholders and the asset sale agreement was then closed on August 31, 2004. The monitor is now sold under the name OV-Watch and Sernova receives royalties on the net sales.
In February, through a Share Exchange Agreement, PCS was acquired by Mecca Medi-Tech Inc. (MEC), a venture capital pool company trading on the Canadian Venture Exchange. The combined new entity was named Pheromone Sciences Corporation.
Pheromone Sciences first commercial product brought to market was the PSC Fertility Monitor. The monitor set a new benchmark in family planning and provides a more reliable and user-friendly approach to natural, cycle-based fertility status measurement. The PSC Fertility Monitor is a non-invasive method of predicting ovulation and the fertile window of women through the measurements of sweat ion changes on the surface of the skin. It is a small wristwatch-like device, containing an interactive microprocessor combined with a biochemical sensor allowing it to produce data that predicts the fertility status of the user (not-fertile, fertile or ovulating). The computed results can then be viewed on the LCD screen of the device and/or the user can be alerted via optional audio signals.
PCS succeeded in characterizing a human (female) pheromone, naming it PSC Synchronin.
Pheromone Sciences Corporation (PCS) was a private corporation founded by Doug Marett, M.Sc. in 1992.